Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8980542 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL5500934 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL237904 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL6645242 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL7610788 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL6644555 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL5502787 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL2668921 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL12656375 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 | |
| SCHEMBL8980781 | 1.00 | PLA2G1B (0.60) | PLA2G1BPLA2G2AS1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-04-23 | — | — | US | disclosed |
| US-12582609-B2 | Cancer vaccines | MODERNATX, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260041643-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250352666-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO (US) | 2025-11-20 | — | — | US | disclosed |
| US-12453706-B2 | Bispecific stealth lipid nanoparticle compositions for cell targeting | GENERATION BIO CO. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250186358-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO. | 2025-06-12 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12133923-B2 | Lipid nanoparticle compositions and uses thereof | RECODE THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240299580-A1 | APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. | 2024-09-12 | — | — | US | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| EP-0748863-A2 | Traction drive fluid composition | COSMO RESEARCH INSTITUTE (JP) | 1996-12-18 | — | — | EP | disclosed |
| US-5536425-A | DURABILITY | SONY CORPORATION (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5453539-A | Durability | SONY CORPORATION (JP) | 1995-09-26 | — | — | US | disclosed |
| EP-0519406-A2 | Novel perfluoropolyether derivatives, and lubricants and magnetic recording medium using the same | SONY CORPORATION (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-4898895-A | Antifouling pain having a polyacrylate component with pendent silyl or siloxane groups | NIPPON OIL AND FATS CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299580-A1 | APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LDLR, APOB, APOL1 | PLA2G1B 2003/4885PLA2G2A 783/4885S1PR2 2209/4885 |
| US-12133923-B2 | Lipid nanoparticle compositions and uses thereof | LIPA, NPC1L1, NPC1 | PLA2G1B 173/4885PLA2G2A 148/4885S1PR2 824/4885 |
| US-12582609-B2 | Cancer vaccines | RNMT, MICA, NSUN2 | PLA2G1B 1899/4885PLA2G2A 717/4885S1PR2 961/4885 |
| US-20250352666-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, EYA3, EYA2 | PLA2G1B 301/4885PLA2G2A 108/4885S1PR2 806/4885 |
| US-12453706-B2 | Bispecific stealth lipid nanoparticle compositions for cell targeting | CD47, MCL1, PLTP | PLA2G1B 102/4885PLA2G2A 42/4885S1PR2 111/4885 |
| US-20260041643-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD4, CD47, PBK | PLA2G1B 1280/4885PLA2G2A 169/4885S1PR2 81/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | PLA2G1B 144/4885PLA2G2A 67/4885S1PR2 999/4885 |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD47, PLTP, CETP | PLA2G1B 799/4885PLA2G2A 148/4885S1PR2 349/4885 |
| US-20250186358-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD47, MCL1, PLTP | PLA2G1B 102/4885PLA2G2A 42/4885S1PR2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.